Table 2.
Febrile neutropenia risk of chemotherapy regimens administered to patients
| On-body injector | Other physician choice | All patients | |
|---|---|---|---|
| (n = 1624) | (n = 951) | (N = 2575) | |
| FN risk of chemotherapy regimen—n (%) | |||
| High | 1079 (66.4) | 493 (51.8) | 1572 (61.0) |
| Intermediate | 545 (33.6) | 458 (48.2) | 1003 (39.0) |
| Chemotherapy regimen—n (%) | |||
| High risk for FN (> 20%) | |||
| TC | 573 (35.3) | 254 (26.7) | 827 (32.1) |
| TCHP | 392 (24.1) | 182 (19.1) | 574 (22.3) |
| TCH | 82 (5.0) | 32 (3.4) | 114 (4.4) |
| TAC | 23 (1.4) | 9 (0.9) | 32 (1.2) |
| R-da EPOCH | 8 (0.5) | 15 (1.6) | 23 (0.9) |
| Dose-adjusted EPOCH | 1 (< 0.1) | 0 (0.0) | 1 (< 0.1) |
| R-ICE | 0 (0.0) | 1 (0.1) | 1 (< 0.1) |
| Intermediate risk for FN (10–20%) | |||
| R-CHOP | 163 (10.0) | 89 (9.4) | 252 (9.8) |
| Etoposide and carboplatin | 70 (4.3) | 70 (7.4) | 140 (5.4) |
| AC | 63 (3.9) | 47 (4.9) | 110 (4.3) |
| Docetaxel | 59 (3.6) | 71 (7.5) | 130 (5.0) |
| Carboplatin and paclitaxel | 59 (3.6) | 55 (5.8) | 114 (4.4) |
| Bendamustine and rituximab | 53 (3.3) | 71 (7.5) | 124 (4.8) |
| AC → T | 47 (2.9) | 21 (2.2) | 68 (2.6) |
| CHOP | 10 (0.6) | 1 (0.1) | 11 (0.4) |
| TH | 5 (0.3) | 1 (0.1) | 6 (0.2) |
| Cisplatin and docetaxel | 4 (0.2) | 4 (0.4) | 8 (0.3) |
| Cabazitaxel | 4 (0.2) | 1 (0.1) | 5 (0.2) |
| Paclitaxel | 3 (0.2) | 2 (0.2) | 5 (0.2) |
| CMF classic | 2 (0.1) | 22 (2.3) | 24 (0.9) |
| Cisplatin and etoposide | 2 (0.1) | 3 (0.3) | 5 (0.2) |
| Carboplatin nab-paclitaxel | 1 (< 0.1) | 0 (0.0) | 1 (< 0.1) |
AC, doxorubicin, cyclophosphamide; AC → T, doxorubicin, cyclophosphamide → docetaxel; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CMF, cyclophosphamide, methotrexate, fluorouracil; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; FN, febrile neutropenia; ICE, ifosfamide, carboplatin, etoposide; R, rituximab; R-da EPOCH, rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; TAC, docetaxel, doxorubicin, cyclophosphamide; TC, docetaxel, cyclophosphamide; TCH, docetaxel, carboplatin, trastuzumab; TCHP, docetaxel, carboplatin, trastuzumab, pertuzumab; TH, docetaxel, trastuzumab